Unlike CRCC, where targeted therapy against vascular endothelial growth factor (VEGF) has dramatically improved the outcome of patients [4], VEGF-targeted agents show poor efficacy in PRCC. This evidence concerns the gene VEGFA and chromophobe renal cell carcinoma.